BFA
PTGX icon

BlackRock Fund Advisors’s Protagonist Therapeutics PTGX Stock Holding History

BlackRock Fund Advisors’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$5.37M Buy
244,386
+37,931
+18% +$846K ﹤0.01% 2904
2016
Q3 		$4.36M Buy
+206,455
New +$2.82M ﹤0.01% 2903

Other funds holding PTGX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PI
Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BlackRock Fund Advisors's PTGX Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Protagonist Therapeutics (PTGX) stake by 18% in Q4 2016, buying an estimated $846K and bringing the position to 244,386 shares worth $5.37M. The position accounts for ﹤0.01% of the portfolio, ranked #2904.

BlackRock Fund Advisors first reported a position in PTGX in Q3 2016 and has held it in 2 quarters since. 38 funds tracked by Wall St. Rank hold PTGX as of Q4 2016.

  • BlackRock Fund Advisors held 244,386 shares of Protagonist Therapeutics worth $5.37M as of Q4 2016.
  • BlackRock Fund Advisors bought 37,931 Protagonist Therapeutics shares in Q4 2016, an estimated $846K.
  • Protagonist Therapeutics made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #2904 holding.
  • BlackRock Fund Advisors first reported a position in Protagonist Therapeutics in Q3 2016 and has held it in 2 quarters since.
  • 38 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.